Table 2.
The biomarkers serum concentrations in the psoriatic patients compared to the control group.
| Biomarker | Psoriasis | Control |
Univariate logistic regression analysis (psoriasis versus control) |
Multivariate logistic regression analysis (psoriasis versus control) |
||
|---|---|---|---|---|---|---|
| M ± SD | M ± SD | OR (95% CI) | p | OR (95% CI) | p | |
| sRANKL (pmol/L) | 94.589 ± 74.330 | 87.235 ± 67.028 | 1.003 (0.996, 1.011) | 0.357 | — | — |
| COMP (ng/mL) | 592.111 ± 337.873 | 417.388 ± 215.801 | 1.002 (1.000, 1.004) | 0.020 | 1.003 (1.000, 1.005) | 0.027 |
| Osteoprotegerin (pmol/L) | 3.682 ± 1.270 | 3.070 ± 0.741 | 1.823 (1.073, 3.098) | 0.027 | 1.993 (1.001, 4.156) | 0.048 |
| Osteoprotegerin/sRANKL | 9.104 ± 9.317 | 14.801 ± 21.747 | 1.025 (0.985, 1.066) | 0.223 | — | — |
| IL-20 (pg/mL) | 24.052 ± 17.965 | 7.517 ± 4.632 | 1.232 (1.116, 1.360) | <0.001 | 1.258 (1.115, 1.420) | <0.001 |